Skip to main content
Erschienen in: Herz 2/2021

29.09.2020 | Original articles

Pulmonary hypertension due to left heart disease with pulmonary arterial wedge pressure ≤15 mm Hg

verfasst von: Dongxu Xu, Hao Zhang, Huiling Cheng, Tianbao Xu, Wei Sun, Yanhui Sheng, Rong Yang, Dongjie Xu, Fang Zhou, Yanli Zhou, Fang Xu, Hongyan Zhu, IokFai Cheang, Qiang Ding, Yan Chen, Pei Zhao, Xiangqing Kong, Xinli Li, Haifeng Zhang

Erschienen in: Herz | Sonderheft 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Pulmonary hypertension due to left heart disease (PH-LHD) is the most prevalent type of pulmonary hypertension (PH). The hemodynamic diagnostic standard of pulmonary arterial wedge pressure (PAWP) >15 mm Hg that is traditionally recommended by guidelines is being challenged.

Methods

To address this problem, we analyzed the data of 154 patients with PH-LHD admitted to our center from April 2013 to March 2018. Pharmacological or nonpharmacological treatment of underlying left heart disease was offered to all 154 patients.

Results

In total, there were 24 patients (15.6%) with PAWP ≤15 mm Hg. Comparison of echocardiography and right heart catheterization parameters between the two groups (PAWP >15 mm Hg and PAWP ≤15 mm Hg) showed that the group with PAWP ≤15 mm Hg had smaller left ventricular diameter, higher cardiac output, lower pressure and higher oxygen saturation in the pulmonary artery, right atrium, right ventricle, and superior vena cava. No significant difference was found regarding dilated cardiomyopathy, diabetes mellitus, hypertension, atrial fibrillation, and left heart valvular disease, but a significant difference was found for coronary heart disease (higher morbidity in group with PAWP ≤15 mm Hg) between the two groups.

Conclusion

We found that 15.6% of the patients with PH-LHD under pharmacological or nonpharmacological treatment had PAWP ≤15 mm Hg. These results suggest that the diagnostic criterion of PAWP and the characteristics for this group of patients should be further investigated.
Literatur
1.
Zurück zum Zitat Farber HW, Gibbs S (2015) Under pressure: pulmonary hypertension associated with left heart disease. Eur Respir Rev 24:665–673CrossRef Farber HW, Gibbs S (2015) Under pressure: pulmonary hypertension associated with left heart disease. Eur Respir Rev 24:665–673CrossRef
2.
Zurück zum Zitat Guha A, Amione-Guerra J, Park MH (2016) Epidemiology of pulmonary hypertension in left heart disease. Prog Cardiovasc Dis 59:3–10CrossRef Guha A, Amione-Guerra J, Park MH (2016) Epidemiology of pulmonary hypertension in left heart disease. Prog Cardiovasc Dis 59:3–10CrossRef
3.
Zurück zum Zitat Weitsman T, Weisz G, Farkash R et al (2017) Pulmonary hypertension with left heart disease: prevalence, temporal shifts in etiologies and outcome. Am J Med 130:1272–1279CrossRef Weitsman T, Weisz G, Farkash R et al (2017) Pulmonary hypertension with left heart disease: prevalence, temporal shifts in etiologies and outcome. Am J Med 130:1272–1279CrossRef
4.
Zurück zum Zitat Guazzi M, Borlaug BA (2012) Pulmonary hypertension due to left heart disease. Circulation 126:975–990CrossRef Guazzi M, Borlaug BA (2012) Pulmonary hypertension due to left heart disease. Circulation 126:975–990CrossRef
5.
Zurück zum Zitat Dupuis J, Guazzi M (2015) Pathophysiology and clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases. Can J Cardiol 31:416–429CrossRef Dupuis J, Guazzi M (2015) Pathophysiology and clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases. Can J Cardiol 31:416–429CrossRef
6.
Zurück zum Zitat Breitling S, Ravindran K, Goldenberg NM et al (2015) The pathophysiology of pulmonary hypertension in left heart disease. Am J Physiol Lung Cell Mol Physiol 309:L924–941CrossRef Breitling S, Ravindran K, Goldenberg NM et al (2015) The pathophysiology of pulmonary hypertension in left heart disease. Am J Physiol Lung Cell Mol Physiol 309:L924–941CrossRef
7.
Zurück zum Zitat Verbrugge FH, Dupont M, Bertrand PB et al (2015) Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension. Eur J Heart Fail 17:320–328CrossRef Verbrugge FH, Dupont M, Bertrand PB et al (2015) Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension. Eur J Heart Fail 17:320–328CrossRef
8.
Zurück zum Zitat Lafçı G, Diken AI, Gedik HS et al (2012) Alterations in pulmonary artery pressure following mitral valve replacement. Turk Kardiyol Dern Ars 40:235–241CrossRef Lafçı G, Diken AI, Gedik HS et al (2012) Alterations in pulmonary artery pressure following mitral valve replacement. Turk Kardiyol Dern Ars 40:235–241CrossRef
9.
Zurück zum Zitat Healey JS, Davies RA, Tang ASL (2004) Improvement of apparently fixed pulmonary hypertension with cardiac resynchronization therapy. J Heart Lung Transplant 23:650–652CrossRef Healey JS, Davies RA, Tang ASL (2004) Improvement of apparently fixed pulmonary hypertension with cardiac resynchronization therapy. J Heart Lung Transplant 23:650–652CrossRef
10.
Zurück zum Zitat Galiè N, Humbert M, Vachiery J‑L et al (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Heart J 37:67–119CrossRef Galiè N, Humbert M, Vachiery J‑L et al (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Heart J 37:67–119CrossRef
11.
Zurück zum Zitat Vachiéry J‑L, Adir Y, Barberà JA et al (2013) Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62:D100–108CrossRef Vachiéry J‑L, Adir Y, Barberà JA et al (2013) Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62:D100–108CrossRef
12.
Zurück zum Zitat Rosenkranz S, Gibbs JSR, Wachter R et al (2016) Left ventricular heart failure and pulmonary hypertension. Eur Heart J 37:942–954CrossRef Rosenkranz S, Gibbs JSR, Wachter R et al (2016) Left ventricular heart failure and pulmonary hypertension. Eur Heart J 37:942–954CrossRef
13.
Zurück zum Zitat Hussain N, Charalampopoulos A, Ramjug S et al (2016) Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management. Pulm Circ 6:3–14CrossRef Hussain N, Charalampopoulos A, Ramjug S et al (2016) Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management. Pulm Circ 6:3–14CrossRef
14.
Zurück zum Zitat Assad TR, Hemnes AR, Larkin EK et al (2016) Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension. J Am Coll Cardiol 68:2525–2536CrossRef Assad TR, Hemnes AR, Larkin EK et al (2016) Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension. J Am Coll Cardiol 68:2525–2536CrossRef
15.
Zurück zum Zitat Liu LCY, Hummel YM, van der Meer P et al (2017) Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. Eur J Heart Fail 19:116–125CrossRef Liu LCY, Hummel YM, van der Meer P et al (2017) Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. Eur J Heart Fail 19:116–125CrossRef
16.
Zurück zum Zitat Hoendermis ES, Liu LCY, Hummel YM et al (2015) Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 36:2565–2573CrossRef Hoendermis ES, Liu LCY, Hummel YM et al (2015) Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 36:2565–2573CrossRef
17.
Zurück zum Zitat Koller B, Steringer-Mascherbauer R, Ebner CH et al (2017) Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-trial). Heart Lung Circ 26:433–441CrossRef Koller B, Steringer-Mascherbauer R, Ebner CH et al (2017) Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-trial). Heart Lung Circ 26:433–441CrossRef
18.
Zurück zum Zitat Vachiéry J‑L, Delcroix M, Al-Hiti H et al (2018) Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 51:1701886CrossRef Vachiéry J‑L, Delcroix M, Al-Hiti H et al (2018) Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 51:1701886CrossRef
Metadaten
Titel
Pulmonary hypertension due to left heart disease with pulmonary arterial wedge pressure ≤15 mm Hg
verfasst von
Dongxu Xu
Hao Zhang
Huiling Cheng
Tianbao Xu
Wei Sun
Yanhui Sheng
Rong Yang
Dongjie Xu
Fang Zhou
Yanli Zhou
Fang Xu
Hongyan Zhu
IokFai Cheang
Qiang Ding
Yan Chen
Pei Zhao
Xiangqing Kong
Xinli Li
Haifeng Zhang
Publikationsdatum
29.09.2020
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe Sonderheft 2/2021
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-020-04983-3

Weitere Artikel der Sonderheft 2/2021

Herz 2/2021 Zur Ausgabe

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Weniger Extremitätenischämien mit dualer Plättchenhemmung

02.05.2024 Thrombozytenaggregationshemmer Nachrichten

Eine Behandlung mit Ticagrelor zusätzlich zu ASS kann das Risiko für Revaskularisierungen und Amputationen von Extremitäten bei Diabetikern mit stabiler KHK deutlich reduzieren, vor allem für solche mit PAVK. Dafür spricht eine Auswertung der Interventionsstudie THEMIS.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.